7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis

Launched by NHS GREATER GLASGOW AND CLYDE · Jan 16, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating how a medication called Filgotinib helps relieve pain in patients with rheumatoid arthritis (RA). Researchers want to understand how Filgotinib works by looking at brain activity and inflammation in the body. They believe that the way the brain processes pain and the level of inflammation in the joints both play a role in how effectively Filgotinib reduces pain. This study is important because it may help explain why patients can feel pain relief quickly after starting the medication.

To participate in the trial, individuals must be adults aged 18 to 75 with moderate to severe active rheumatoid arthritis who have been prescribed Filgotinib. Participants will undergo brain imaging tests using a special MRI machine to observe changes in their brain and body while taking the medication. It’s important to note that people with certain health conditions, severe physical limitations, or those who are pregnant cannot join the study. Overall, this research aims to provide valuable insights into how Filgotinib works and improve pain management for people living with rheumatoid arthritis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Patients with moderate to severe active RA who have been prescribed filgotinib in line with the Summary of Product Characterisation and are:
• • Adults ≥18 years \< 75 years.
• • Right-handed (to reduce neuroimaging heterogeneity).
• Exclusion Criteria:
• • Inability to provide written informed consent.
• • Severe physical impairment (e.g. blindness, deafness, paraplegia).
• • Pregnant or breast feeding.
• • Severe claustrophobia precluding MRI.
• • Contraindications to MRI.
• • Major confounding neurological disease including MS, Stroke, Traumatic Brain Injury.
• • Previous targeted synthetic (e.g. baricitinib, tofacitinib) DMARD exposure for RA.